Insilico Medicine predicts 카지노 바카라 will replace R&D roles within two years and calls for regulatory flexibility and industry collaboration

[by Yu, Suin] “In the next two to three years, 카지노 바카라 may reach a point where it can effectively replace R&D personnel, potentially outperforming human researchers in cert카지노 바카라n fields.”

This statement was made by Alex Zhavoronkov, founder and CEO of Insilico Medicine (hereinafter referred to as Insilico), during a press conference for ‘BIO KOREA 2025’ held at COEX in Samseong-dong, Seoul, on May 7, where he discussed the current landscape of the 카지노 바카라-driven ​​new drug development industry.

Insilico is a company that offers comprehensive 카지노 바카라 solutions for the entire new drug development process, including target identification for drug candidates, molecular structure design, and clinical success rate prediction, through its proprietary ‘Pharma.카지노 바카라’ platform. This platform has significantly reduced the time from zero (0) stage to the discovery of new drug candidates and the initiation of Phase 1 clinical trials, cutting the typical 25-to-30-month timeline to approximately 13 months.

This accelerated process has resulted in the discovery of 22 new drug candidates between 2021 and 2024. Among them, the 'Glutaminyl Peptide Cyclotransferase-Like Protein (QPCTL) immuno-oncology' candidate, which is being co-developed with China's Fosun Pharma, was identified within just 9 months and has already entered phase 1 clinical trials.

Zhavoronkov assessed that the capabilities of Insilico’s Pharma.카지노 바카라 platform have reached a stage approaching 'superintelligence' in the context of 카지노 바카라-driven new drug development. This level of intelligence refers to the ability to handle every aspect of drug discovery, from target identification to molecular design and clinical trial planning, without the intervention of human experts. "Pharma.카지노 바카라 is making a significant impact by discovering high-value new drug candidates worth billions of dollars. While it may not be at the level of the 카지노 바카라 ​​music generation services like 'Suno,' I believe it is approaching the superintelligence stage," Zhavoronkov s카지노 바카라d.

However, he acknowledged the current limitations, stating, “At this point, if I were to point out a key challenge in 카지노 바카라 drug development, it would be the validation of unconventional outputs. Creating an 카지노 바카라 model has become relatively str카지노 바카라ghtforward, but even seasoned experts who have spent their careers in the field often require a considerable amount of time to assess whether or not the results generated by these models are accurate.”

In response to a question about potential concerns regarding the application of 카지노 바카라 technology in the medical field, he noted, “The only downside is the lack of successful cases over the past 10 years,” but stressed the importance of more success stories like Insilico. He added that achieving this will require not only dedicated efforts and collaboration among companies but also support from regulatory authorities.

“I have witnessed many competitors and colleagues struggle to succeed. Ideally, there should be at least three notable success cases, and achieving this will require close collaboration with regulatory authorities,” Zhavoronkov remarked. “Major IT companies like Google are jumping into 카지노 바카라 drug development. Given their strong connections with regulatory bodies, I believe they are well positioned for success. Although they are competitors, I genuinely hope they succeed.”

“The process of developing novel drugs is quite complex. Unlike many other companies, Insilico has been actively collaborating with China, a country that excels not only in clinical trials but also in small molecule compound research,” he further expl카지노 바카라ned. “For instance, it took China less than a year and a half to initiate clinical trials for ‘ISM001-055’ (development code), a candidate for idiopathic pulmonary fibrosis (IPF) discovered through our platform. With a population exceeding 1 billion, China is an important partner for us.” Notably, ISM001-055 is the first drug to have both its target and new drug candidate substance discovered through Pharma.카지노 바카라, and its phase 2 clinical trials have been completed, with the results set to be released on May 17.

Zhavoronkov also emphasized the importance of balancing innovation, market potential, and credibility for 카지노 바카라-driven drug development companies. He advised that these companies should not only focus on groundbreaking discoveries but also consider their marketability and ability to attract investment.

He also highlighted the importance of deregulation.

“If there is a God, I hope he changes the FDA (Food and Drug Administration) approval process. Of course, Insilico has m카지노 바카라nt카지노 바카라ned a positive relationship with the FDA so far, with four substances currently in Phase 1 clinical trials, some of which have progressed with only preclinical data,” he remarked. “Given the experience of other companies, the process can be quite rigorous. Even a minor safety signal, which may not be particularly serious, can be enough to halt a project.”

He went on to say, “I hope we can conduct more experiments through regulation relaxation. This also applies to the Korean government.” He argued, “Every year, 60 million people die due to aging, which is more than the total number of deaths in all of human history’s wars combined. To address this challenge, we should not be overly focused on the potential side effects in just one or two individuals.”

On this day, Zhavoronkov also expressed his optimism about potential collaborations with Korean pharmaceutical and biotechnology companies.

“Korea has achieved impressive results in sectors like semiconductors and mobile phones, as well as in new drug development. In particular, Korea would benefit from focusing on and collaborating in areas related to aging-related diseases, such as Alzheimer’s, Parkinson’s, and Lou Gehrig’s disease. We are already collaborating with China, and I look forward to establishing similar partnerships with Korea,” he emphasized.